In the context of hematologic malignancies, our study revealed that ELANE expression is significantly elevated in AML samples relative to healthy controls and correlates with poorer overall survival, thereby supporting its role as a prognostic biomarker in leukemia [40]. The gene discussed is ELANE; the disease is hematologic disorder.